COCP earnings analysis
What we found in COCP's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The extracted Form 10-Q text does not include the financial statements or MD&A, so revenue, margins, EPS, cash flow, balance-sheet trends, and segment performance cannot be assessed from the available filing content. Management reported effective disclosure controls as of June 30, 2026 and no material changes in internal controls or legal proceedings. No financial guidance was provided, and Item 1.A risk factors was marked not applicable to smaller reporting companies.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Disclosure controls remain effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026, under Exchange Act Rules 13a-15(e) and 15d-15(e).
- No material control changes
- The company reported no material changes in internal control over financial reporting during the quarter ended June 30, 2026.
- No new material legal proceedings
- No material changes were reported to the legal-proceedings disclosures from the March 31, 2026 Form 10-Q during the reporting period.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Inherent internal-control limitations
- The filing states that internal controls have inherent limitations and may not prevent or detect misstatements; future evaluations may be affected by changing conditions or deteriorating compliance. The disclosure references Rules 13a-15(e) and 15d-15(e).
What they said about what is next.
No quantitative revenue or EPS outlook was provided in the extracted 10-Q text. The filing does not discuss an updated financial outlook.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 15, 2026
- Cocrystal Pharma reported Q1 2026 with a net loss of $2.30M, slightly improved from a loss of $2.30M in Q1 2025. Total revenue remained at $0, marking a continuation of its pre-revenue status, although the company…
- 10-K · March 31, 2026
- Cocrystal Pharma is a clinical-stage antiviral drug developer advancing multiple programs: CDI-988 (oral pan-viral protease inhibitor) entered a Phase 1b human challenge study in February 2026, CC-42344 (PB2 influenza…
- 10-Q · August 14, 2024
- Cocrystal reported a Q2 net loss of $5,343,000 (EPS -$0.53), widening from -$4,166,000 (-$0.41) year-over-year; six-month net loss was $9,299,000. Operating cash outflow remains large at $8,202,000 for the six months…
- 10-Q · November 13, 2023
- Cocrystal Pharma reported a Q3 net loss of $4,165,000 (EPS $(0.41)), an improvement from Q3 2022 EPS $(0.70). Cash and restricted cash totaled $29.8 million at September 30, 2023 after raising $4.0 million in April…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing COCP makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever